4d Molecular Therapeutics, Inc. · NASDAQ:FDMT
Venrock Healthcare Capital Partners III, L.P.'s stake in 4d Molecular Therapeutics, Inc. fell to 1.50% (Schedule 13G/A)
Event Mar 31, 2025 · Filed May 15, 2025
Venrock Healthcare Capital Partners III, L.P.'s stake in 4d Molecular Therapeutics, Inc. fell to 1.50%, 677,600 shares, as a passive investor on Mar 31, 2025. Filed May 15, 2025 (Schedule 13G/A).
- Stake
- 1.50%
- Shares
- 677,600
- Intent
- Passive
- What changed
- Fell below 5%
- Filed together
- 7 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 1.50% | 677,600 |
| VHCP Co-Investment Holdings III, LLC | 1.50% | 677,600 |
| Venrock Healthcare Capital Partners EG, L.P. | 1.50% | 677,600 |
| VHCP Management III, LLC | 1.50% | 677,600 |
| VHCP Management EG, LLC | 1.50% | 677,600 |
| Nimish Shah | 1.50% | 677,600 |
| Bong Y Koh | 1.50% | 677,600 |
Source
Related
- 4d Molecular Therapeutics, Inc.
- Venrock Healthcare Capital Partners III, L.P.
- 4d Molecular Therapeutics, Inc. shareholders
- Schedule 13G/A · Venrock Healthcare Capital Partners III, L.P. · Feb 14, 2025
- Form 4 · Bizily Scott · Oct 20, 2026
- Form 4 · Kirn David · Oct 7, 2026
- Form 4 · Bizily Scott · Sep 22, 2026
- Form 4 · Kirn David · Sep 16, 2026
- Form 4 · Bizily Scott · Sep 3, 2026